浏览全部资源
扫码关注微信
沈阳药科大学 生命科学与生物制药学院,沈阳 110016
Published:20 November 2023,
Published Online:18 August 2023,
Received:21 May 2023,
扫 描 看 全 文
吴忠,吴斌,魏秀岩.慢加急性肝衰竭关键基因的生物信息学探究及潜在中药预测验证[J].中国实验方剂学杂志,2023,29(22):79-87.
WU Zhong,WU Bin,WEI Xiuyan.Bioinformatic Exploration of Hub Genes in Acute-on-chronic Liver Failure and Verification of Traditional Chinese Medicine Candidates[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(22):79-87.
吴忠,吴斌,魏秀岩.慢加急性肝衰竭关键基因的生物信息学探究及潜在中药预测验证[J].中国实验方剂学杂志,2023,29(22):79-87. DOI: 10.13422/j.cnki.syfjx.20231016.
WU Zhong,WU Bin,WEI Xiuyan.Bioinformatic Exploration of Hub Genes in Acute-on-chronic Liver Failure and Verification of Traditional Chinese Medicine Candidates[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(22):79-87. DOI: 10.13422/j.cnki.syfjx.20231016.
目的
2
应用生物信息学方法探究慢加急性肝衰竭(ACLF)的关键基因,预测潜在治疗中药并实验验证其作用机制。
方法
2
利用Perl和R软件分析GSE142255数据集获取差异表达基因(DEGs),基于CytoHubba插件的5种算法鉴定DEGs蛋白质-蛋白质相互作用(PPI)网络中的关键基因,并借助受试者工作特征(ROC)曲线和GSE168048数据集对关键基因进行验证分析;Coremine Medical数据库映射关键基因对应中药并分析其四气、五味、归经;中药系统药理学数据库与分析平台(TCMSP)和DEGs获取高频中药治疗ACLF的交集靶点,Cytoscape软件绘制关键基因-高频中药-活性成分-交集靶点网络图,并进行基因本体(GO)、京都基因与基因组百科全书(KEGG)富集分析及体外实验。
结果
2
共获取388个DEGs,7个关键基因分别为CD4、整合素亚基
α
M(ITGAM)、CD2、淋巴细胞特异蛋白酪氨酸激酶(LCK)原癌基因,CC基序趋化因子配体5(CCL5)、基质金属蛋白酶-9(MMP-9)、Fc ε受体IG(FCER1G)。潜在治疗中药多为寒性、苦味、归肝经的药物,其中高频中药如白花蛇舌草、灵芝、黄芪和活性成分槲皮素、山柰酚、
β
-谷甾醇的潜在治疗价值重大。富集分析显示,中药除调控关键基因外,仍对自噬、氧化应激、炎症因子等多靶点、多通路发挥作用。L02细胞实验表明,与
D
-氨基半乳糖(
D
-GaLN)组比较,槲皮素组肿瘤坏死因子-
α
(TNF-
α
)、白细胞介素-6(IL-6)、丙二醛(MDA)水平和泛素结合蛋白p62、MMP-9蛋白表达明显降低(
P
<
0.05,
P
<
0.01),而超氧化物歧化酶(SOD)、谷胱甘肽(GSH)水平和微管相关蛋白1轻链3 Ⅱ/Ⅰ(LC3 Ⅱ/Ⅰ)蛋白表达明显增加(
P
<
0.05,
P
<
0.01),且3-甲基腺嘌呤(3-MA)预处理可抑制槲皮素对L02细胞自噬激活作用。
结论
2
基于ACLF的关键基因,预测所得潜在治疗中药及活性成分具有重大研究价值,其中槲皮素对
D
-GaLN诱导L02细胞氧化应激、炎症反应的抑制及MMP-9的调控而具有治疗ACLF的潜力,其机制可能与其激活自噬相关。
Objective
2
To explore the hub genes of acute-on-chronic liver failure (ACLF) using bioinformatics methods, predict the potential traditional Chinese medicines (TCMs) against ACLF, and verify the treatment mechanism based on experiments.
Method
2
Perl and R were used to analyze the GSE142255 dataset to obtain the differentially expressed genes (DEGs), from which the hub genes in the protein-protein interaction of DEGs were identified by five algorithms of the CytoHubba plug-in. The receiver operating characteristic (ROC) curve and GSE168048 dataset were then used to verify the hub genes. Coremine Medical was employed to map the TCMs corresponding to the hub genes and then the natures, tastes, and meridian tropism of the TCMs were analyzed. The TCM systems pharmacology database and analysis platform (TCMSP) and DEGs were used to obtain the common targets shared by high-frequency TCMs and ACLF, and Cytoscape was used to establish the "hub gene-high-frequency TCM-active ingredient-common target" network. Furthermore, gene ontology (GO) annotation, Kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis, and
in vitro
experiments were performed.
Result
2
A total of 388 DEGs were obtained, in which the 7 hub genes encoded CD4 integrin subunit alpha M (ITGAM), CD2, lymphocyte-specific protein tyrosine kinase (LCK) proto-oncogene, C-C motif chemokine ligand 5 (CCL5), matrix metallopeptidase-9 (MMP-9), and Fc epsilon receptor IG (FCER1G). The TCM candidates for treating ACLF were mainly cold, bitter, and had tropism to the liver meridian, among which the high-frequency TCMs (Hedyotis Diffusae Herba, Ganoderma, and Astragali Radix) and the active ingredients
(quercetin, kaempferol, and beta-sitosterol) had significant therapeutic potential. The enrichment analysis results showed that TCMs acted on multiple targets and pathways such as autophagy, oxidative stress, and inflammatory cytokines in addition to regulating hub genes. L02 cell experiments showed that the quercetin group had lower levels of tumor necrosis factor-
α
(TNF-
α
), interleukin-6 (IL-6), and malondialdehyde (MDA), lower protein levels of ubiquitin-binding protein p62 and MMP-9, and higher levels of superoxide dismutase (SOD), glutathione (GSH), and microtubule-associated protein 1 light chain 3 Ⅱ/Ⅰ (LC3 Ⅱ/Ⅰ) than the
D
-galactosamine (
D
-GaLN) group (
P
<
0.05,
P
<
0.01). In addition, the pretreatment with 3-methyladenine (3-MA) inhibited the activating effect of quercetin on the autophagy of L02 cells.
Conclusion
2
The potential TCMs and active ingredients predicted based on the hub genes of ACLF have a great research value. Quercetin has the potential to treat ACLF by inhibiting the
D
-GaLN-induced oxidative stress and inflammatory response in L02 cells and regulating the expression of MMP-9, which may be associated with the activation of autophagy.
慢加急性肝衰竭关键基因生物信息学中药预测自噬
acute-on-chronic liver failurehub genesbioinformaticstraditional Chinese medicine predictionautophagy
YANG M,PENG B,ZHUANG Q,et al.Models to predict the short-term survival of acute-on-chronic liver failure patients following liver transplantation[J].BMC Gastroenterol,2022,22(1):80.
蒙荫杰,邱华,毛德文.慢加急性肝衰竭的发病机制和治疗现状[J].西南医科大学学报,2023,46(3):267-271.
谭年花,曹钰楠,唐陈琴,等.基于巨噬细胞极化研究“赤芍-附片”治疗慢加急性肝衰竭的作用机制[J].中国实验方剂学杂志,2022,28(15):35-41.
MEZZANO G,JUANOLA A,CARDENAS A,et al.Global burden of disease: Acute-on-chronic liver failure, a systematic review and Meta-analysis[J].Gut,2022,71(1):148-155.
刘敏,徐涛,何莹,等.基于网络药理学探讨茵陈四逆汤治疗慢加急性肝衰竭的分子机制[J].中西医结合肝病杂志,2022,32(6):535-539.
林勇凯.基于数据挖掘研究中西医结合治疗乙型肝炎相关慢加急性肝衰竭的疗效[D].广东:广州中医药大学,2021.
宋金玥,任锋,张向颖,等.山柰酚干预对D-氨基半乳糖/脂多糖诱导小鼠急性肝衰竭的保护作用[J].中国中西医结合杂志,2017,37(5):569-574.
CHIN C H,CHEN S H,WU H H,et al.cytoHubba: identifying hub objects and sub-networks from complex interactome[J].BMC Syst Biol,2014,8(Suppl 4):S11.
张道平,姚昆鹏,刘起立,等.基于生物信息学探讨肝癌相关细胞焦亡基因及潜在中药预测[J].中草药,2022,53(23):7467-7476.
FANG P,LIANG J,JIANG X,et al.Quercetin attenuates D-GaLN-Induced L02 cell damage by suppressing oxidative stress and mitochondrial apoptosis via inhibition of HMGB1[J].Front Pharmacol,2020,11:608.
CHEN Q,WANG Y,JIAO F Z,et al.Histone deacetylase 6 inhibitor ACY1215 offers a protective effect through the autophagy pathway in acute liver failure[J].Life Sci,2019,238:116976.
LEVRERO M, ZUCMAN-ROSSI J.Mechanisms of HBV-induced hepatocellular carcinoma[J].J Hepatol,2016,64(1):S84-S101.
张凯.肝脏面积与腹部面积比评估HBV相关慢加急性肝衰竭远期肝癌发生的研究[D].福建:福建医科大学,2021.
凌春萍,毛德文,王晓明.解毒化瘀颗粒对慢加急性肝衰竭患者外周血CD4+CD25+Treg细胞的影响[J].辽宁中医杂志,2023,50(7):155-157.
邓婷婷,李莉,关瀛,等.炎性相关标志物判断HBV相关慢加急性肝衰竭预后的研究进展[J].临床肝胆病杂志,2022,38(10):2346-2351.
MOGANTI K,LI F,SCHMUTTERMAIER C,et al.Hyperglycemia induces mixed M1/M2 cytokine profile in primary human monocyte-derived macrophages[J].Immunobiology,2017,222(10):952-959.
ZHAO H,WU L,ZHANG Y,et al.Betulinic acid prevents liver fibrosis by binding Lck and suppressing Lck in HSC activation and proliferation[J].J Ethnopharmacol,2022,296:115459.
王兆京,袁逸枫,庄海文,等.基质金属蛋白酶-9在急性肝炎肝衰竭中的表达及其临床意义[J].中华临床医师杂志:电子版,2011,5(8):2212-2216.
LILI CHEN,QIANFEI ZHANG,CHANG YU,et al.Functional roles of CCL5/RANTES in liver disease[J].Liver Res,2020,4(1):28-34.
SWEET R A,NICKERSON K M,CULLEN J L,et al.B Cell-extrinsic MyD88 and Fcer1g negatively regulate autoreactive and normal B cell immune responses[J].J Immunol,2017,199(3):885-893.
中国中西医结合学会.慢加急性肝衰竭中西医结合诊疗专家共识[J].北京中医药,2021,40(9):946-955.
张修举,郭瑞,张引强,等.温阳利湿化瘀方对乙肝相关慢加急性肝衰竭患者早期血清内毒素和炎症因子的影响[J].中国中医急症,2022,31(1):38-41.
王秀峰,陈桂容,林华明,等.中医药治疗慢加急性肝衰竭的研究进展[J].大众科技,2022,24(7):120-124.
吕建林,毛德文,柳琳琳,等.中西医结合治疗慢加急性肝衰竭的临床研究进展[J].中西医结合肝病杂志,2021,31(11):1047-1050.
李斌华,谢青,闫雪华.乙型肝炎病毒相关肝衰竭中医用药规律研究进展[J].陕西中医,2022,43(4):538-540.
陈月桥,廖南盛,罗业浩,等.“扶阳培土”法辅助治疗肝衰竭的临床研究进展[J].实用中医内科杂志,2022,36(10):30-33.
MILTONPRABU S,TOMCZYK M,SKALICKA-WOŹNIAK K,et al.Hepatoprotective effect of quercetin: From chemistry to medicine[J].Food Chem Toxicol,2017,108(Pt B):365-374.
FANG P,DOU B,LIANG J,et al.Quercetin reduces oxidative stress and apoptosis by inhibiting HMGB1 and its translocation, thereby alleviating liver injury in ACLF rats[J].Evid Based Complement Alternat Med,2021,2021:2898995.
高丽枫,李秀丽,张雪辉,等.槲皮素在肝细胞癌中的作用机制研究进展[J].赤峰学院学报:自然科学版,2021,37(6):65-70.
WANG H,CHEN L,ZHANG X,et al.Kaempferol protects mice from D-GalN/LPS-induced acute liver failure by regulating the ER stress-Grp78-CHOP signaling pathway[J].Biomed Pharmacother,2019,111:468-475.
YIN Y,LIU X,LIU J,et al.Beta-sitosterol and its derivatives repress lipopolysaccharide/d-galactosamine-induced acute hepatic injury by inhibiting the oxidation and inflammation in mice[J].Bioorg Med Chem Lett,2018,28(9):1525-1533.
曾菠.乙肝相关慢加急肝衰竭患者肝脏基因表达谱特征及“PINRO”发病机制假说[D].上海:上海交通大学,2015.
杜心怡,李俊峰,毛小荣.乙肝肝硬化后慢加急性肝衰竭的研究进展[J].中国实用内科杂志,2022,42(5):427-430.
DU X X,SHI Y,YANG Y,et al.DAMP molecular IL-33 augments monocytic inflammatory storm in hepatitis B-precipitated acute-on-chronic liver failure[J].Liver Int,2018,38(2):229-238.
HAN H,DESERT R,DAS S,et al.Danger signals in liver injury and restoration of homeostasis[J].J Hepatol,2020,73(4):933-951.
窦博,马重阳,侯伟欣,等.基于TLR4/NF-κB/iNOS通路的截断逆挽方药物血清对L02细胞氧化应激损伤的影响[J].中国中医药信息杂志,2022,29(4):87-91.
CHUANG S M,LU J H,LIN K L,et al.Epigenetic regulation of COX‑2 expression by DNA hypomethylation via NF‑κB activation in ketamine‑induced ulcerative cystitis[J].Int J Mol Med,2019,44(3):797-812.
周帆,彭君伟,范伏岗,等.自噬与氧化应激在非酒精性脂肪性肝病发病机制中的关系[J].临床肝胆病杂志,2018,34(8):1805-1808.
顾鑫楠,胡菲菲,苗蕙,等.金银花水提物改善非酒精性脂肪性肝炎的探索[J].中国实验方剂学杂志,2022,28(23):87-96.
JIAO L,ZHANG H L,LI D D,et al.Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 (hexokinase 2)[J].Autophagy,2018,14(4):671-684.
TANG L,WANG X,ZHAO R,et al.Yi-Qi-Jian-Pi formula ameliorates immune function in acute-on-chronic liver failure by upregulating autophagy and mitochondrial biogenesis in CD8+ T lymphocytes[J].J Ethnopharmacol,2023,308:116276.
郑婷婷.自噬相关蛋白Beclin1和LC3-Ⅱ在乙型肝炎相关慢加急性肝衰竭中的表达及意义[D].南宁:广西医科大学,2018.
HERON-MILHAVET L,KHOUYA N,FERNANDEZ A,et al.Akt1 and Akt2: Differentiating the aktion[J].Histol Histopathol,2011,26(5):651-662.
LIU W,JING Z T,XUE C R,et al.PI3K/Akt inhibitors aggravate death receptor-mediated hepatocyte apoptosis and liver injury[J].Toxicol Appl Pharmacol,2019,381:114729.
陆霓虹,刘洪璐,夏加伟,等.免疫功能和SAA、MMP-9、MMP-14在抗结核药物性肝损伤中的临床评估[J].昆明医科大学学报,2022,43(4):50-54.
陆霓虹,杨永锐.基质金属蛋白酶与抗结核药物性肝损伤的相关性研究进展[J].中国医药科学,2022,12(14):23-26.
KOTHARI P,PESTANA R,MESRAOUA R,et al.IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages[J].J Immunol,2014,192(1):349-357.
HORI T,UEMOTO S,WALDEN L B,et al.Matrix metalloproteinase-9 as a therapeutic target for the progression of fulminant liver failure with hepatic encephalopathy: A pilot study in mice[J].Hepatol Res,2014,44(6):651-662.
0
Views
21
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution